Inadequate dosing and incomplete treatment regimens, coupled with the ability of the
tuberculosis bacilli to cause latent infections that are tolerant of currently used drugs, have …

Infections are a growing global threat, and the number of resistant species of microbial
pathogens is alarming. However, the rapid development of cross-resistant or multidrug …

Over the past 2000 years, tuberculosis (TB) has killed more people than any other infectious
disease. In 2021, TB claimed 1.6 million lives worldwide, making it the second leading …

Tuberculosis, a disease of poverty is a communicable infection with a reasonably high
mortality rate worldwide. 10 Million new cases of TB were reported with approx 1.4 million …

Tuberculosis (TB) remains a major health problem worldwide. The infectious agent,
Mycobacterium tuberculosis, has a unique ability to survive within the host, alternating …

Pyridine and pyridine-fused ring systems are ubiquitous in medicinal research and
demonstrate such diverse pharmacological benefits as anticonvulsant therapies, treatment …

Increasing interest in the potent anti-tuberculosis activity and the novel target (QcrB) of
imidazo [1, 2-a] pyridine-3-carboxamides encouraged extended structure–activity …

Causing approximately 10 million incident cases and 1.3–1.5 million deaths every year,
Mycobacterium tuberculosis remains a global health problem. The risk is further …

Mycobacterium tuberculosis strictly depends on oxygen to multiply, and the terminal
oxidases are a vital part of the oxidative phosphorylation pathway. The bacterium possesses …

The imidazopyridines are a promising new class of antitubercular agents with potent activity
in vitro and in vivo. We isolated mutants of Mycobacterium tuberculosis resistant to a …